From: Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study
Preoperative
chemotherapy
response
Apatinib plus SOX regimen, n (%)
SOX regimen, n (%)
P value
CR
0
0.497
PR
15 (71.4)
16 (55.2)
SD
4 (14.3)
9 (31.0)
PD
2 (9.5)
4 ((13.8)
ORR
15(71.4)
16(55.2)
0.382
DCR
19(90.5)
25(86.2)
0.986